Navigation Links
Delcath Announces Completion of Regulatory Notification Process in New Zealand
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Delcath Systems (NASDAQ: DCTH) announced today that the Company has, through its designated sponsor, completed the product notification process for the Delcath Hepatic CHEMOSAT® Delivery system with the Medicines and Medical Device Safety Authority (MEDSAFE) in New Zealand. Completion of this process permits Delcath to legally supply and distribute CHEMOSAT to the New Zealand market. The Company expects to begin supplying the system through an authorized distributor in 2012.

Commenting on the announcement, Eamonn P. Hobbs, President and CEO of Delcath, said, "Completion of the notification process in New Zealand is part of our plans to expand our addressable markets by leveraging our CE Mark for CHEMOSAT. New Zealand is just one of several markets that require CE Mark as a prerequisite that we expect to open over the next few years. We have also completed our filing with the Australian Therapeutic Goods Administration, and expect approval by year-end. We also intend to seek regulatory acceptance in other markets in Asia, Latin America and the Middle East. With market access in New Zealand and anticipated acceptance in Australia by the end of the year, our plans for introducing chemosaturation therapy into the Pacific region have begun."

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase 3 metastatic melanoma study, and the Company recently completed a multi-arm Phase 2 trial to treat other
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
2. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
3. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
4. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
5. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
6. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
7. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
8. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
9. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
10. Delcath on Preliminary List of Additions to Russell Microcap® Index
11. Delcath to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... , May 19, 2013  The non-surgical ... low temperature radiofrequency (RF) energy is effective in ... or reduces the need for medication 10 years ... presented today at the Digestive Disease Week (DDW) ... Florida . "The sustained ...
(Date:5/18/2013)... 2013 Although colonoscopy exams prevent many colon ... sensitive method for detecting colorectal cancers 2 , the ... 3 . EndoChoice ® Inc. today unveiled research ... the accuracy of this procedure and greatly reduces the ... discussing these clinical trial results and featuring the Fuse ...
(Date:5/18/2013)... May 18, 2013 The Open Paradigm ... Occupy Psychiatry , and leading organizations ... announces a social media campaign showcasing video testimonials ... model, which focuses on pathology and illness rather ... the American Psychiatric Association,s (APA) rollout of its ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3
(Date:5/19/2013)... Actos lawsuit claims continue ... in U.S. District Court, Western District of Louisiana. ... the Court has modified the litigation’s Bellwether Nomination process, ... than four. The next Status Conference in the federal ... re: Actos Product Liability Litigation, MDL No. 2299) , ...
(Date:5/19/2013)... May 19, 2013 The muscles in ... their functionality and one of the biggest and most ... nervous system. The peripheral system comprises of peripheral nerves ... cord. These nerves ensure that the limbs and hands, ... when these nerves get damaged due to trauma or ...
(Date:5/19/2013)... 19, 2013 Today, Zane Benefits, ... business health insurance . Zane Benefits, which provides ... health benefits, is the leader in health care ... reimbursement arrangements . , According to Zane Benefits’ ... intrinsically know the value of small business health ...
(Date:5/19/2013)... May 19, 2013 Grinding your teeth ... losing sleep, or annoying your spouse. At the same ... CNY Central (“Snoring and Teeth Grinding Could Be a ... teeth grinding can be hard to prevent. Apparently, Obstructive ... and one of its symptoms is a habit of ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 According ... Market Analysis and Forecast (2013 – 2018): By ... Defense, Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, ... of image sensor market was $8.00 billion in ... in 2018, at an estimated CAGR of 3.84% ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3
... a special supplement, "Evaluation of the American Academy of ... Annals of Family Medicine reports on the results ... medical home concept in primary care practices. ... in 36 diverse U.S. primary care practices, an independent ...
... ... radio listeners on The Penn Project Show that, “The obesity crisis and related problems, such ... America needs to reverse that pro-inflammatory trend with anti-inflammatory diets, such as the Zone Diet." ... New Haven, CT (Vocus) ...
... ... Hispanic families found that untreated tooth decay in mothers almost doubled the odds of tooth ... and their children, the authors say. , ... (Vocus) June 15, 2010 -- A UCSF study examining the oral health of ...
... in wiring previously thought to be fixed , TUESDAY, ... fixed in early life, and circuits in the adult ... study involving mice. , U.S. researchers found that neurons ... alter their relationships with one another after single whiskers ...
... study led by UNC researchers that looks at newly diagnosed lung ... the first to give reasons why patients don,t go to lung ... most profound finding was the fact that African Americans with two ... four out of 100, whereas white patients in the same situation ...
... for those with MRSA in respiratory tract, study shows ... patients with methicillin-resistant staphylococcus aureus (MRSA) in their respiratory ... drug-resistant bacteria, researchers have found. , The new study, ... Journal of the American Medical Association , included 19,833 ...
Cached Medicine News:Health News:Results of first national demonstration project to implement patient-centered medical home released 2Health News:Results of first national demonstration project to implement patient-centered medical home released 3Health News:Results of first national demonstration project to implement patient-centered medical home released 4Health News:Results of first national demonstration project to implement patient-centered medical home released 5Health News:Results of first national demonstration project to implement patient-centered medical home released 6Health News:Results of first national demonstration project to implement patient-centered medical home released 7Health News:Clear Channel's “Penn Project” Features Dr. Barry Sears, Zone Diet Creator, About Obesity in America 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 3Health News:UNC study helps explain why black patients with lung cancer have surgery less often than whites 2Health News:UNC study helps explain why black patients with lung cancer have surgery less often than whites 3Health News:Drug-Resistant Staph Threatens Cystic Fibrosis Patients 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: